You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Partner Fund Management||0||2,210,020||0||6.2%|
|Partner Fund Management GP||0||2,210,020||0||6.2%|
|Partner Investment Management||0||32,071||0||0.1%|
|Partner Investment Management GP||0||32,071||0||0.1%|
|Brian D. Grossman||0||2,242,091||0||6.3%|
|Christopher M. James||0||2,242,091||0||6.3%|
Page 1 of 13 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Information Statement Pursuant to Rules
13d-1 and 13d-2
Under the Securities Exchange Act of
(Amendment No. )*
Aerie Pharmaceuticals, Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
Date of Event Which Requires Filing of the
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).